Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Baxter
Federal Trade Commission
Express Scripts
Queensland Health
Chinese Patent Office
Citi
Cantor Fitzgerald
UBS
Farmers Insurance

Generated: August 17, 2017

DrugPatentWatch Database Preview

Carbamazepine - Generic Drug Details

« Back to Dashboard

What are the generic sources for carbamazepine and what is the scope of carbamazepine freedom to operate?

Carbamazepine
is the generic ingredient in eight branded drugs marketed by Usl Pharma, Taro, Novartis, Validus Pharms, Shire, Torrent Pharms, Wockhardt, Teva, Taro Pharm, Warner Chilcott, Lundbeck Pharms Llc, Inwood Labs, Jubilant Cadista, Apotex Inc, Pliva, Taro Pharm Inds, Teva Pharms, Actavis Elizabeth, and Mylan Ireland Ltd, and is included in twenty-nine NDAs. There are five patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Carbamazepine has fifty-five patent family members in nineteen countries.

There are twenty-seven drug master file entries for carbamazepine. Forty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: carbamazepine

Tradenames:8
Patents:5
Applicants:19
NDAs:29
Drug Master File Entries: see list27
Suppliers / Packagers: see list42
Bulk Api Vendors: see list99
Clinical Trials: see list132
Patent Applications: see list6,568
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:carbamazepine at DailyMed

Tentative approvals for CARBAMAZEPINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe100MGCAPSULE, EXTENDED RELEASE; ORAL
► Subscribe► Subscribe300MGCAPSULE, EXTENDED RELEASE; ORAL
► Subscribe► Subscribe200MGCAPSULE, EXTENDED RELEASE; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire
CARBATROL
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL020712-003Sep 30, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
Novartis
TEGRETOL
carbamazepine
SUSPENSION;ORAL018927-001Dec 18, 1987ABRXYesYes► Subscribe► Subscribe► Subscribe
Validus Pharms
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-001Dec 10, 2004RXYesNo► Subscribe► Subscribe ► Subscribe
Lundbeck Pharms Llc
CARNEXIV
carbamazepine
SOLUTION;IV (INFUSION)206030-001Oct 7, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Teva Pharms
CARBAMAZEPINE
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL078592-001Sep 20, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: carbamazepine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-003Dec 10, 2004► Subscribe► Subscribe
Novartis
TEGRETOL-XR
carbamazepine
TABLET, EXTENDED RELEASE;ORAL020234-003Mar 25, 1996► Subscribe► Subscribe
Novartis
TEGRETOL-XR
carbamazepine
TABLET, EXTENDED RELEASE;ORAL020234-001Mar 25, 1996► Subscribe► Subscribe
Novartis
TEGRETOL
carbamazepine
TABLET;ORAL016608-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Novartis
TEGRETOL
carbamazepine
SUSPENSION;ORAL018927-001Dec 18, 1987► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: carbamazepine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,200,088Sulfoalkyl ether cyclodextrin compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: carbamazepine

Country Document Number Estimated Expiration
China101959508► Subscribe
New Zealand567290► Subscribe
Japan2015110671► Subscribe
China101309691► Subscribe
Canada2624463► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Covington
QuintilesIMS
Healthtrust
Citi
US Army
Dow
Fuji
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot